Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US30054Y1073
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00Y79N887
EVMN
Evommune, Inc.
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: - · THEMEFOLIO: $HLTH
NAME
Evommune, Inc.
ISIN
US30054Y1073
TICKER
EVMN
MIC
XNYS
REUTERS
EVMN.N
BLOOMBERG
EVMN US
Mi., 04.11.2026       Evommune
US30054Y1073

Evommune, Inc. (“Evommune” or the “Company”) (NYSE: EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 4,966,889 shares of its common stock to a select group of dedicated healthcare i...
Zur Nachricht
Evommune
Charts & Research Termsheets Terminal
Permalink
Mi., 04.11.2026       Evommune
US30054Y1073

Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing therapies for chronic inflammatory diseases, and Hinova Pharmaceuticals Inc. (SSE: 688302) today announced an exclusive license agreement granting Evommune worldwide rights outside of Greater China to develop, manufacture and commercialize...
Zur Nachricht
Evommune
Charts & Research Termsheets Terminal
Permalink
Do., 01.10.2026       Evommune
US30054Y1073

Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today shared additional data from its Phase 2a proof-of-concept trial of EVO301 in adults with moderate-to-severe atopic dermatitis (AD) during a late-breaking or...
Zur Nachricht
Evommune
Charts & Research Termsheets Terminal
Permalink
Mi., 23.09.2026       Evommune
US30054Y1073

Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that data from the Phase 2a trial of EVO301 in moderate-to-severe atopic dermatitis (AD) will be presented in a late-breaking oral session at the...
Zur Nachricht
Evommune
Charts & Research Termsheets Terminal
Permalink
Di., 08.09.2026       Evommune
US30054Y1073

Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized, double-blind, placebo controlled dose-ranging Phase 2b trial evaluating the efficacy and safety of oral Mas...
Zur Nachricht
Evommune
Charts & Research Termsheets Terminal
Permalink
Do., 06.08.2026       Evommune
US30054Y1073

Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the second quarter ended June 30, 2026, and provided a business update. "There are still no first-line oral options for p...
Zur Nachricht
Evommune
Charts & Research Termsheets Terminal
Permalink
Do., 30.07.2026       Evommune
US30054Y1073

Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced the first patient was dosed in its Phase 2b clinical trial evaluating a potent, highly selective oral small molecule antagonist of MRGPRX2, EVO75...
Zur Nachricht
Evommune
Charts & Research Termsheets Terminal
Permalink
Di., 07.07.2026       Evommune
US30054Y1073

Evommune stock dropped approximately 38% after EVO756 missed its Phase 2b primary endpoint in chronic spontaneous urticaria, erasing millions in shareholder value in a single session.NEW YORK, July 7, 2026 /PRNewswire/ -- Evommune, Inc. (NYSE: EVMN) shareholders lost approximately 38% of their investment value on June 29, 2026, when the Company di...
Zur Nachricht
Evommune
Charts & Research Termsheets Terminal
Permalink
Di., 30.06.2026       Evommune
US30054Y1073

Evommune's CEO and CSO sold shares on June 22, 2026, under Rule 10b5-1 plans adopted months earlier -- days before the Company disclosed that EVO756 failed its Phase 2b primary endpoint.NEW YORK, June 30, 2026 /PRNewswire/ -- Evommune, Inc. (NYSE: EVMN) shares dropped approximately 38% after the Company announced that its lead drug candidate EVO75...
Zur Nachricht
Evommune
Charts & Research Termsheets Terminal
Permalink
Mo., 29.06.2026       Evommune
US30054Y1073

Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced top-line results from its randomized, double-blind, placebo controlled, dose-ranging Phase 2b trial evaluating the efficacy and safety of oral MRG...
Zur Nachricht
Evommune
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Do., 07.05.2026       Evommune
US30054Y1073

Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the first quarter ended March 31, 2026, and provided a business update. “We continue to make meaningful progress across o...
Zur Nachricht
Evommune
Charts & Research Termsheets Terminal
Permalink
Mo., 06.04.2026       Evommune
US30054Y1073

Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced it will host a webinar highlighting the migraine treatment landscape and the role of MRGPRX2 inhibition on this debilitating condition on Monday,...
Zur Nachricht
Evommune
Charts & Research Termsheets Terminal
Permalink
Do., 05.03.2026       Evommune
US30054Y1073

Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. “The positive top-line Phase 2a...
Zur Nachricht
Evommune
Charts & Research Termsheets Terminal
Permalink
Fr., 13.02.2026       Evommune
US30054Y1073

Evommune, Inc. (“Evommune” or the “Company”) (NYSE: EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 4,494,279 shares of its common stock to a select group of new and existing mutua...
Zur Nachricht
Evommune
Charts & Research Termsheets Terminal
Permalink
Di., 10.02.2026       Evommune
US30054Y1073

Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced positive top-line results from its randomized, double-blind, placebo-controlled Phase 2a trial evaluating EVO301. This long-acting fusion protein...
Zur Nachricht
Evommune
Charts & Research Termsheets Terminal
Permalink
Do., 11.12.2025       Evommune
US30054Y1073

Evommune, Inc. (NYSE: EVMN) (the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update. “The recent completion of our IPO puts us in a strong positi...
Zur Nachricht
Evommune
Charts & Research Termsheets Terminal
Permalink